Gastrointestinal toxicity of gemtuzumab ozogamicin: real-life data from the AMLCG, SAL, and CELL study groups

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F25%3A00082274" target="_blank" >RIV/65269705:_____/25:00082274 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14110/25:00143855

Výsledek na webu

<a href="https://ashpublications.org/bloodadvances/article/9/13/3336/535732/Gastrointestinal-toxicity-of-gemtuzumab-ozogamicin" target="_blank" >https://ashpublications.org/bloodadvances/article/9/13/3336/535732/Gastrointestinal-toxicity-of-gemtuzumab-ozogamicin</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1182/bloodadvances.2024014570" target="_blank" >10.1182/bloodadvances.2024014570</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Gastrointestinal toxicity of gemtuzumab ozogamicin: real-life data from the AMLCG, SAL, and CELL study groups

Popis výsledku v původním jazyce

The CD33-directed antibody-drug-conjugate &quot;gemtuzumab ozogamicin&quot; (GO) in combination with the 7+3 standard regimen is currently approved for the treatment of CD33+ acute myeloid leukemia (AML). Although the pivotal ALFA-0701 study did not show a significantly increased toxicity using 7+3 + GO compared with 7+3,1 a slightly higher rate of severe gastrointestinal (GI) toxicity was reported (16% vs 10%), and additional evidence of GO-associated GI toxicity was published.2,3 We observed several cases of severe GI toxicity and therefore analyzed patients treated with GO in a real-world setting.Our findings are based on a single-center analysis of patients treated at the University Hospital Munich and a multicenter analysis from 32 hospitals of the German SAL (Study Alliance Leukemia), the AMLCG (AML Cooperative Group), the CELL (Czech Leukemia Study Group), and other university hospitals of Germany. For further information about the methods used in our analyses, refer to supplemental Methods.

Název v anglickém jazyce

Gastrointestinal toxicity of gemtuzumab ozogamicin: real-life data from the AMLCG, SAL, and CELL study groups

Popis výsledku anglicky

The CD33-directed antibody-drug-conjugate &quot;gemtuzumab ozogamicin&quot; (GO) in combination with the 7+3 standard regimen is currently approved for the treatment of CD33+ acute myeloid leukemia (AML). Although the pivotal ALFA-0701 study did not show a significantly increased toxicity using 7+3 + GO compared with 7+3,1 a slightly higher rate of severe gastrointestinal (GI) toxicity was reported (16% vs 10%), and additional evidence of GO-associated GI toxicity was published.2,3 We observed several cases of severe GI toxicity and therefore analyzed patients treated with GO in a real-world setting.Our findings are based on a single-center analysis of patients treated at the University Hospital Munich and a multicenter analysis from 32 hospitals of the German SAL (Study Alliance Leukemia), the AMLCG (AML Cooperative Group), the CELL (Czech Leukemia Study Group), and other university hospitals of Germany. For further information about the methods used in our analyses, refer to supplemental Methods.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30205 - Hematology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Blood Advances

ISSN

2473-9529

e-ISSN

2473-9537

Svazek periodika

9

Číslo periodika v rámci svazku

13

Stát vydavatele periodika

NL - Nizozemsko

Počet stran výsledku

4

Strana od-do

3336-3339

Kód UT WoS článku

001533729300007

EID výsledku v databázi Scopus

2-s2.0-105009615117